Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 8/20 | 0.32 |
| ▸ | CA1 | P00915 | 7/20 | 0.32 |
| ▸ | CA9 | Q16790 | 5/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA7 | P43166 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829122 | 0.88 | PDPK1 (0.38) | CYP2D6POLBCA2CA1CA9 | |
| SCHEMBL4836651 | 0.84 | CA1 (0.40) | PTGS2CA2CA1CA9CA4 | |
| SCHEMBL4837035 | 0.82 | CA9 (0.47) | PTGS2CA2CA1CA9CA12 | |
| SCHEMBL4833719 | 0.79 | LRRK2 (0.33) | PTGS2CA2CA1CA9CA4 | |
| SCHEMBL4833484 | 0.71 | HSD11B1 (0.43) | PTGS2POLBKDM4EMAPK1 | |
| SCHEMBL4825906 | 0.70 | ALDH1A1 (0.39) | PTGS2POLBCA2CA1CA9 | |
| SCHEMBL4833912 | 0.69 | PTGS2 (0.36) | PTGS2CA2CA1CA9CA4 | |
| SCHEMBL4831432 | 0.69 | PTGS2 (0.45) | PTGS2CYP2D6POLBCA2CA1 | |
| SCHEMBL4835178 | 0.66 | ACSS2 (0.37) | POLBKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL4833405 | 0.66 | PGR (0.54) | KDM4ESMN1; SMN2MAPK1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | claimed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | claimed |
| EP-1425284-A2 | FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-09 | — | — | EP | claimed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | claimed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | disclosed |
| EP-1425284-A2 | FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004142-A1 | Chemical compounds | TIE1, KDR, TEK | PTGS2 110/4885CYP2D6 2559/4885POLB 928/4885 |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TIE1, TEK, KDR | PTGS2 205/4885CYP2D6 1693/4885POLB 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.